Intrasaccular flow disruption for ruptured aneurysms: An international multicenter study

Jose Danilo Bengzon Diestro; Mahmoud Dibas; Nimer Adeeb; Robert W. Regenhardt; Justin E. Vranic; Adrien Guenego; Sovann V. Lay; Leonardo Renieri; Ali Al Balushi; Eimad Shotar; Kevin Premat; Kareem El Naamani; Guillaume Saliou; Markus A. Möhlenbruch; Ivan Lylyk; Paul M. Foreman; Jay A. Vachhani; Vedran Zupančić; Muhammad U. Hafeez; Caleb Rutledge; Hamid Rai; Vincent M. Tutino; Shervin Mirshani; Sherief Ghozy; Pablo Harker; Naif M. Alotaibi; James D. Rabinov; Yifan Ren; Clemens M. Schirmer; Oded Goren; Mariangela Piano; Anna Luisa Kuhn; Caterina Michelozzi; Stephanie Elens; Robert M. Starke; Ameer Hassan; Arsalaan Salehani; Anh Nguyen; Jesse Jones; Marios Psychogios; Julian Spears; Carmen Parra-Fariñas; Maria Bres Bullrich; Michael Mayich; Mohamed M. Salem; Jan Karl Burkhardt; Brian T. Jankowitz; Ricardo A. Domingo; Thien Huynh; Rabih Tawk; Christian Ulfert; Boris Lubicz; Pietro Panni; Ajit S. Puri; Guglielmo Pero; Christoph J. Griessenauer; Hamed Asadi; Adnan Siddiqui; Andrew F. Ducruet; Felipe C. Albuquerque; Rose Du; Peter Kan; Vladimir Kalousek; Pedro Lylyk; Srikanth Reddy Boddu; Christopher J. Stapleton; Jared Knopman; Pascal Jabbour; Stavropoula Tjoumakaris; Frédéric Clarençon; Nicola Limbucci; Mohammad A. Aziz-Sultan; Hugo H. Cuellar-Saenz; Christophe Cognard; Aman B. Patel; Adam A. Dmytriw

doi:10.1136/jnis-2022-019153

Intrasaccular flow disruption for ruptured aneurysms: An international multicenter study

Jose Danilo Bengzon Diestro, Mahmoud Dibas, Nimer Adeeb, Robert W. Regenhardt, Justin E. Vranic, Adrien Guenego, Sovann V. Lay, Leonardo Renieri, Ali Al Balushi, Eimad Shotar, Kevin Premat, Kareem El Naamani, Guillaume Saliou, Markus A. Möhlenbruch, Ivan Lylyk, Paul M. Foreman, Jay A. Vachhani, Vedran Zupančić, Muhammad U. Hafeez, Caleb RutledgeHamid Rai, Vincent M. Tutino, Shervin Mirshani, Sherief Ghozy, Pablo Harker, Naif M. Alotaibi, James D. Rabinov, Yifan Ren, Clemens M. Schirmer, Oded Goren, Mariangela Piano, Anna Luisa Kuhn, Caterina Michelozzi, Stephanie Elens, Robert M. Starke, Ameer Hassan, Arsalaan Salehani, Anh Nguyen, Jesse Jones, Marios Psychogios, Julian Spears, Carmen Parra-Fariñas, Maria Bres Bullrich, Michael Mayich, Mohamed M. Salem, Jan Karl Burkhardt, Brian T. Jankowitz, Ricardo A. Domingo, Thien Huynh, Rabih Tawk, Christian Ulfert, Boris Lubicz, Pietro Panni, Ajit S. Puri, Guglielmo Pero, Christoph J. Griessenauer, Hamed Asadi, Adnan Siddiqui, Andrew F. Ducruet, Felipe C. Albuquerque, Rose Du, Peter Kan, Vladimir Kalousek, Pedro Lylyk, Srikanth Reddy Boddu, Christopher J. Stapleton, Jared Knopman, Pascal Jabbour, Stavropoula Tjoumakaris, Frédéric Clarençon, Nicola Limbucci, Mohammad A. Aziz-Sultan, Hugo H. Cuellar-Saenz, Christophe Cognard, Aman B. Patel, Adam A. Dmytriw

Research output: Contribution to journal › Article › peer-review

3 Scopus citations

Abstract

Background: The Woven EndoBridge (WEB) device is a novel intrasaccular flow disruptor tailored for bifurcation aneurysms. We aim to describe the degree of aneurysm occlusion at the latest follow-up, and the rate of complications of aneurysms treated with the WEB device stratified according to rupture status. Methods: Our data were taken from the WorldWideWeb Consortium, an international multicenter cohort including patients treated with the WEB device. Aneurysms were classified into two groups: ruptured and unruptured. We compared clinical and radiologic outcomes of both groups. Propensity score matching (PSM) was done to match according to age, gender, bifurcation, location, prior treatment, neck, height, dome width, daughter sac, incorporated branch, pretreatment antiplatelets, and last imaging follow-up. Results: The study included 676 patients with 691 intracranial aneurysms (529 unruptured and 162 ruptured) treated with the WEB device. The PSM analysis had 55 pairs. In both the unmatched (85.8% vs 84.3%, p=0.692) and matched (94.4% vs 83.3%, p=0.066) cohorts there was no significant difference in the adequate occlusion rate at the last follow-up. Likewise, there were no significant differences in both ischemic and hemorrhagic complications between the two groups. There was no documented aneurysm rebleeding after WEB device implantation. Conclusion: There was no significant difference in both the radiologic outcomes and complications between unruptured and ruptured aneurysms. Our findings support the feasibility of treatment of ruptured aneurysms with the WEB device.

Original language	English (US)
Article number	neurintsurg-2022-019153
Journal	Journal of neurointerventional surgery
DOIs	https://doi.org/10.1136/jnis-2022-019153
State	Accepted/In press - 2022
Externally published	Yes

Keywords

Aneurysm

ASJC Scopus subject areas

Surgery
Clinical Neurology

Access to Document

10.1136/jnis-2022-019153

Cite this

Diestro, J. D. B., Dibas, M., Adeeb, N., Regenhardt, R. W., Vranic, J. E., Guenego, A., Lay, S. V., Renieri, L., Al Balushi, A., Shotar, E., Premat, K., El Naamani, K., Saliou, G., Möhlenbruch, M. A., Lylyk, I., Foreman, P. M., Vachhani, J. A., Zupančić, V., Hafeez, M. U., ... Dmytriw, A. A. (Accepted/In press). Intrasaccular flow disruption for ruptured aneurysms: An international multicenter study. Journal of neurointerventional surgery, Article neurintsurg-2022-019153. https://doi.org/10.1136/jnis-2022-019153

Diestro, JDB, Dibas, M, Adeeb, N, Regenhardt, RW, Vranic, JE, Guenego, A, Lay, SV, Renieri, L, Al Balushi, A, Shotar, E, Premat, K, El Naamani, K, Saliou, G, Möhlenbruch, MA, Lylyk, I, Foreman, PM, Vachhani, JA, Zupančić, V, Hafeez, MU, Rutledge, C, Rai, H, Tutino, VM, Mirshani, S, Ghozy, S, Harker, P, Alotaibi, NM, Rabinov, JD, Ren, Y, Schirmer, CM, Goren, O, Piano, M, Kuhn, AL, Michelozzi, C, Elens, S, Starke, RM, Hassan, A, Salehani, A, Nguyen, A, Jones, J, Psychogios, M, Spears, J, Parra-Fariñas, C, Bres Bullrich, M, Mayich, M, Salem, MM, Burkhardt, JK, Jankowitz, BT, Domingo, RA, Huynh, T, Tawk, R, Ulfert, C, Lubicz, B, Panni, P, Puri, AS, Pero, G, Griessenauer, CJ, Asadi, H, Siddiqui, A, Ducruet, AF, Albuquerque, FC, Du, R, Kan, P, Kalousek, V, Lylyk, P, Boddu, SR, Stapleton, CJ, Knopman, J, Jabbour, P, Tjoumakaris, S, Clarençon, F, Limbucci, N, Aziz-Sultan, MA, Cuellar-Saenz, HH, Cognard, C, Patel, AB & Dmytriw, AA 2022, 'Intrasaccular flow disruption for ruptured aneurysms: An international multicenter study', Journal of neurointerventional surgery. https://doi.org/10.1136/jnis-2022-019153

@article{ea7b124c21444c83b7cb73107ff6846d,

title = "Intrasaccular flow disruption for ruptured aneurysms: An international multicenter study",

abstract = "Background: The Woven EndoBridge (WEB) device is a novel intrasaccular flow disruptor tailored for bifurcation aneurysms. We aim to describe the degree of aneurysm occlusion at the latest follow-up, and the rate of complications of aneurysms treated with the WEB device stratified according to rupture status. Methods: Our data were taken from the WorldWideWeb Consortium, an international multicenter cohort including patients treated with the WEB device. Aneurysms were classified into two groups: ruptured and unruptured. We compared clinical and radiologic outcomes of both groups. Propensity score matching (PSM) was done to match according to age, gender, bifurcation, location, prior treatment, neck, height, dome width, daughter sac, incorporated branch, pretreatment antiplatelets, and last imaging follow-up. Results: The study included 676 patients with 691 intracranial aneurysms (529 unruptured and 162 ruptured) treated with the WEB device. The PSM analysis had 55 pairs. In both the unmatched (85.8% vs 84.3%, p=0.692) and matched (94.4% vs 83.3%, p=0.066) cohorts there was no significant difference in the adequate occlusion rate at the last follow-up. Likewise, there were no significant differences in both ischemic and hemorrhagic complications between the two groups. There was no documented aneurysm rebleeding after WEB device implantation. Conclusion: There was no significant difference in both the radiologic outcomes and complications between unruptured and ruptured aneurysms. Our findings support the feasibility of treatment of ruptured aneurysms with the WEB device.",

keywords = "Aneurysm",

author = "Diestro, {Jose Danilo Bengzon} and Mahmoud Dibas and Nimer Adeeb and Regenhardt, {Robert W.} and Vranic, {Justin E.} and Adrien Guenego and Lay, {Sovann V.} and Leonardo Renieri and {Al Balushi}, Ali and Eimad Shotar and Kevin Premat and {El Naamani}, Kareem and Guillaume Saliou and M{\"o}hlenbruch, {Markus A.} and Ivan Lylyk and Foreman, {Paul M.} and Vachhani, {Jay A.} and Vedran Zupan{\v c}i{\'c} and Hafeez, {Muhammad U.} and Caleb Rutledge and Hamid Rai and Tutino, {Vincent M.} and Shervin Mirshani and Sherief Ghozy and Pablo Harker and Alotaibi, {Naif M.} and Rabinov, {James D.} and Yifan Ren and Schirmer, {Clemens M.} and Oded Goren and Mariangela Piano and Kuhn, {Anna Luisa} and Caterina Michelozzi and Stephanie Elens and Starke, {Robert M.} and Ameer Hassan and Arsalaan Salehani and Anh Nguyen and Jesse Jones and Marios Psychogios and Julian Spears and Carmen Parra-Fari{\~n}as and {Bres Bullrich}, Maria and Michael Mayich and Salem, {Mohamed M.} and Burkhardt, {Jan Karl} and Jankowitz, {Brian T.} and Domingo, {Ricardo A.} and Thien Huynh and Rabih Tawk and Christian Ulfert and Boris Lubicz and Pietro Panni and Puri, {Ajit S.} and Guglielmo Pero and Griessenauer, {Christoph J.} and Hamed Asadi and Adnan Siddiqui and Ducruet, {Andrew F.} and Albuquerque, {Felipe C.} and Rose Du and Peter Kan and Vladimir Kalousek and Pedro Lylyk and Boddu, {Srikanth Reddy} and Stapleton, {Christopher J.} and Jared Knopman and Pascal Jabbour and Stavropoula Tjoumakaris and Fr{\'e}d{\'e}ric Claren{\c c}on and Nicola Limbucci and Aziz-Sultan, {Mohammad A.} and Cuellar-Saenz, {Hugo H.} and Christophe Cognard and Patel, {Aman B.} and Dmytriw, {Adam A.}",

note = "Funding Information: JDBD: Honoraria from Medtronic. Travel grant from Microvention. MD: No relevant relationships NA: No relevant relationships RWR: Grants from National Institutes of Health, Heitman foundation, Society of vascular and interventional neurology; Advisory board participation for Rapid medical; Site PI for Microvention and Penumbra JEV: No relevant relationships AG : No relevant relationships SVL: No relevant relationships LR: No relevant relationships AAB: No relevant relationships ES: No relevant relationships KP: No relevant relationships KEL: No relevant relationships GS : No relevant relationships MAM: No relevant relationships IL: No relevant relationships PMR: No relevant relationships JAV: Fees from MicroVention for proctoring cases for new physician users of the Woven EndoBridge device; Medtronic travel expense V{\v Z}: Participation on the data safety monitoring board or advisory board for KBC Sestre Milosrdnice, Zagreb / OB Nova Gradi{\v s}ka MUH: No relevant relationships CR: No relevant relationships HR: No relevant relationships VMT: No relevant relationships SM: No relevant relationships SG: No relevant relationships PH: No relevant relationships NA: No relevant relationships JDR: No relevant relationships YR: No relevant relationships CMS: No relevant relationships OG: No relevant relationships MP: No relevant relationships ALK: No relevant relationships CM: No relevant relationships SE: No relevant relationships RMS: Supported by the NREF, Joe Niekro Foundation, Brain Aneurysm Foundation, Bee Foundation, and the National Institutes of Health (R01NS111119-01A1, UL1TR002736, and KL2TR002737) through the Miami Clinical and Translational Science Institute, from the National Center for Advancing Translational Sciences and the National Institute on Minority Health and Health Disparities. AH: Consulting or speaker fees from Medtronic, MicroVention, Stryker, Penumbra, Cerenovus, Genentech, GE Healthcare, Scientia, Balt, Viz.ai, Insera Therapeutics, Proximie, NeuroVasc, NovaSignal, Vesalio, and Galaxy Therapeutics. AS: No relevant relationships AN: No relevant relationships JJ: Consulting and speaker fees from Cerenovus MP: No relevant relationships JS: No relevant relationships CPF: No relevant relationships MBB: No relevant relationships MM: Grants from Balt, Medtronic, MicroVention, and Stryker. MMS: No relevant relationships JB: No relevant relationships BTJ: No relevant relationships RAD: No relevant relationships TH: No relevant relationships RT: Medtronic Stocks CU: No relevant relationships BL : No relevant relationships PP: No relevant relationships ASP: Grants from NIH, Microvention, Cerenovus, Medtronic and Stryker; Consulting fees from Neurovascular, Stryker NeurovascularBalt, Q{\textquoteright}Apel Medical, Cerenovus, Microvention, Imperative Care, Agile, Merit, CereVasc and Arsenal Medical; stock options from InNeuroCo, Agile, Perfuze, Galaxy and NTI GP: No relevant relationships CJG: Grants to institution from Medtronic and Penumbra; consulting fees from Stryker and MicroVention. HA: Proctoring fees from MicroVention. Grants to institution from the National Institutes of Health; consulting fees from Amnis Therapeutics, Apellis Pharmaceuticals, Boston Scientific, Canon Medical Systems, Cardinal Health 200, Cerebrotech Medical Systems, Cerenovus, Cerevatech Medical, Cordis, Corindus, EndoStream Medical, Imperative Care, Integra, IRRAS, Medtronic, MicroVention, Minnetronix Neuro, Penumbra, Q{\textquoteright}Apel Medical, Rapid Medical, Serenity Medical, Silk Road Medical, StimMed, Stryker Neurovascular, Three Rivers Medical, VasSol, Viz.ai, and W.L. Gore & Associates; payment for participation on the steering committees for the Cerenovus EXCELLENT and ARISE II Trial; Medtronic SWIFT PRIME, VANTAGE, EMBOLISE, and SWIFT DIRECT Trials; MicroVention FRED Trial and CONFIDENCE Study; MUSC POSITIVE Trial; Penumbra 3D Separator Trial, COMPASS Trial, INVEST Trial, MIVI Neuroscience EVAQ Trial; Rapid Medical SUCCESS Trial; InspireMD C-GUARDIANS IDE Pivotal Trial; stock or stock options in Adona Medical, Amnis Therapeutics, Bend IT Technologies, BlinkTBI, Buffalo Technology Partners, Cardinal Consultants, Cerebrotech Medical Systems, Cerevatech Medical, Cognition Medical, CVAID, E8, EndoStream Medical, Imperative Care, Instylla, International Medical Distribution Partners, Launch NY, NeuroRadial Technologies, Neurotechnology Investors, Neurovascular Diagnostics, Perflow Medical, Q{\textquoteright}Apel Medical, QAS.ai, Radical Catheter Technologies, Rebound Therapeutics (purchased in 2019 by Integra Lifesciences), Rist Neurovascular (purchased in 2020 by Medtronic), Sense Diagnostics, Serenity Medical, Silk Road Medical, Songbird Therapy, Spinnaker Medical, StimMed, Synchron, Three Rivers Medical, Truvic Medical, Tulavi Therapeutics, Vastrax, VICIS, and Viseon AFD: Consulting fees from Cerenovus, Penumbra, Medtronic, Stryker, Oculus, and Koswire. No relevant relationships RD: No relevant relationships PK: No relevant relationships. VK: No relevant relationships. PL: No relevant relationships SB: No relevant relationships CJS: Participation on the data safety monitoring board or advisory board for Zoll Circulation JK: No relevant relationships PJ: No relevant relationships ST: No relevant relationships FC: No relevant relationships NL: Honoraria for lectures from Cerenovus, Stryker, and CrossMed. MAA: Funding to institution from MicroVention for WEBIT trial; proctoring fees from MicroVention. HHC: No relevant relationships CC: Consulting fees from MicroVention, Stryker, Medtronic, MIVI, and Cerenovus. ABP: Grant to institution from Medtronic; consulting fees from MicroVention, Medtronic, and Q{\textquoteright}Apel; workstation for research from Siemens AAD: No relevant relationships Publisher Copyright: {\textcopyright} Author(s) (or their employer(s)) 2022. No commercial re-use. See rights and permissions. Published by BMJ.",

year = "2022",

doi = "10.1136/jnis-2022-019153",

language = "English (US)",

journal = "Journal of neurointerventional surgery",

issn = "1759-8478",

publisher = "BMJ Publishing Group",

}

TY - JOUR

T1 - Intrasaccular flow disruption for ruptured aneurysms

T2 - An international multicenter study

AU - Diestro, Jose Danilo Bengzon

AU - Dibas, Mahmoud

AU - Adeeb, Nimer

AU - Regenhardt, Robert W.

AU - Vranic, Justin E.

AU - Guenego, Adrien

AU - Lay, Sovann V.

AU - Renieri, Leonardo

AU - Al Balushi, Ali

AU - Shotar, Eimad

AU - Premat, Kevin

AU - El Naamani, Kareem

AU - Saliou, Guillaume

AU - Möhlenbruch, Markus A.

AU - Lylyk, Ivan

AU - Foreman, Paul M.

AU - Vachhani, Jay A.

AU - Zupančić, Vedran

AU - Hafeez, Muhammad U.

AU - Rutledge, Caleb

AU - Rai, Hamid

AU - Tutino, Vincent M.

AU - Mirshani, Shervin

AU - Ghozy, Sherief

AU - Harker, Pablo

AU - Alotaibi, Naif M.

AU - Rabinov, James D.

AU - Ren, Yifan

AU - Schirmer, Clemens M.

AU - Goren, Oded

AU - Piano, Mariangela

AU - Kuhn, Anna Luisa

AU - Michelozzi, Caterina

AU - Elens, Stephanie

AU - Starke, Robert M.

AU - Hassan, Ameer

AU - Salehani, Arsalaan

AU - Nguyen, Anh

AU - Jones, Jesse

AU - Psychogios, Marios

AU - Spears, Julian

AU - Parra-Fariñas, Carmen

AU - Bres Bullrich, Maria

AU - Mayich, Michael

AU - Salem, Mohamed M.

AU - Burkhardt, Jan Karl

AU - Jankowitz, Brian T.

AU - Domingo, Ricardo A.

AU - Huynh, Thien

AU - Tawk, Rabih

AU - Ulfert, Christian

AU - Lubicz, Boris

AU - Panni, Pietro

AU - Puri, Ajit S.

AU - Pero, Guglielmo

AU - Griessenauer, Christoph J.

AU - Asadi, Hamed

AU - Siddiqui, Adnan

AU - Ducruet, Andrew F.

AU - Albuquerque, Felipe C.

AU - Du, Rose

AU - Kan, Peter

AU - Kalousek, Vladimir

AU - Lylyk, Pedro

AU - Boddu, Srikanth Reddy

AU - Stapleton, Christopher J.

AU - Knopman, Jared

AU - Jabbour, Pascal

AU - Tjoumakaris, Stavropoula

AU - Clarençon, Frédéric

AU - Limbucci, Nicola

AU - Aziz-Sultan, Mohammad A.

AU - Cuellar-Saenz, Hugo H.

AU - Cognard, Christophe

AU - Patel, Aman B.

AU - Dmytriw, Adam A.

N1 - Funding Information: JDBD: Honoraria from Medtronic. Travel grant from Microvention. MD: No relevant relationships NA: No relevant relationships RWR: Grants from National Institutes of Health, Heitman foundation, Society of vascular and interventional neurology; Advisory board participation for Rapid medical; Site PI for Microvention and Penumbra JEV: No relevant relationships AG : No relevant relationships SVL: No relevant relationships LR: No relevant relationships AAB: No relevant relationships ES: No relevant relationships KP: No relevant relationships KEL: No relevant relationships GS : No relevant relationships MAM: No relevant relationships IL: No relevant relationships PMR: No relevant relationships JAV: Fees from MicroVention for proctoring cases for new physician users of the Woven EndoBridge device; Medtronic travel expense VŽ: Participation on the data safety monitoring board or advisory board for KBC Sestre Milosrdnice, Zagreb / OB Nova Gradiška MUH: No relevant relationships CR: No relevant relationships HR: No relevant relationships VMT: No relevant relationships SM: No relevant relationships SG: No relevant relationships PH: No relevant relationships NA: No relevant relationships JDR: No relevant relationships YR: No relevant relationships CMS: No relevant relationships OG: No relevant relationships MP: No relevant relationships ALK: No relevant relationships CM: No relevant relationships SE: No relevant relationships RMS: Supported by the NREF, Joe Niekro Foundation, Brain Aneurysm Foundation, Bee Foundation, and the National Institutes of Health (R01NS111119-01A1, UL1TR002736, and KL2TR002737) through the Miami Clinical and Translational Science Institute, from the National Center for Advancing Translational Sciences and the National Institute on Minority Health and Health Disparities. AH: Consulting or speaker fees from Medtronic, MicroVention, Stryker, Penumbra, Cerenovus, Genentech, GE Healthcare, Scientia, Balt, Viz.ai, Insera Therapeutics, Proximie, NeuroVasc, NovaSignal, Vesalio, and Galaxy Therapeutics. AS: No relevant relationships AN: No relevant relationships JJ: Consulting and speaker fees from Cerenovus MP: No relevant relationships JS: No relevant relationships CPF: No relevant relationships MBB: No relevant relationships MM: Grants from Balt, Medtronic, MicroVention, and Stryker. MMS: No relevant relationships JB: No relevant relationships BTJ: No relevant relationships RAD: No relevant relationships TH: No relevant relationships RT: Medtronic Stocks CU: No relevant relationships BL : No relevant relationships PP: No relevant relationships ASP: Grants from NIH, Microvention, Cerenovus, Medtronic and Stryker; Consulting fees from Neurovascular, Stryker NeurovascularBalt, Q’Apel Medical, Cerenovus, Microvention, Imperative Care, Agile, Merit, CereVasc and Arsenal Medical; stock options from InNeuroCo, Agile, Perfuze, Galaxy and NTI GP: No relevant relationships CJG: Grants to institution from Medtronic and Penumbra; consulting fees from Stryker and MicroVention. HA: Proctoring fees from MicroVention. Grants to institution from the National Institutes of Health; consulting fees from Amnis Therapeutics, Apellis Pharmaceuticals, Boston Scientific, Canon Medical Systems, Cardinal Health 200, Cerebrotech Medical Systems, Cerenovus, Cerevatech Medical, Cordis, Corindus, EndoStream Medical, Imperative Care, Integra, IRRAS, Medtronic, MicroVention, Minnetronix Neuro, Penumbra, Q’Apel Medical, Rapid Medical, Serenity Medical, Silk Road Medical, StimMed, Stryker Neurovascular, Three Rivers Medical, VasSol, Viz.ai, and W.L. Gore & Associates; payment for participation on the steering committees for the Cerenovus EXCELLENT and ARISE II Trial; Medtronic SWIFT PRIME, VANTAGE, EMBOLISE, and SWIFT DIRECT Trials; MicroVention FRED Trial and CONFIDENCE Study; MUSC POSITIVE Trial; Penumbra 3D Separator Trial, COMPASS Trial, INVEST Trial, MIVI Neuroscience EVAQ Trial; Rapid Medical SUCCESS Trial; InspireMD C-GUARDIANS IDE Pivotal Trial; stock or stock options in Adona Medical, Amnis Therapeutics, Bend IT Technologies, BlinkTBI, Buffalo Technology Partners, Cardinal Consultants, Cerebrotech Medical Systems, Cerevatech Medical, Cognition Medical, CVAID, E8, EndoStream Medical, Imperative Care, Instylla, International Medical Distribution Partners, Launch NY, NeuroRadial Technologies, Neurotechnology Investors, Neurovascular Diagnostics, Perflow Medical, Q’Apel Medical, QAS.ai, Radical Catheter Technologies, Rebound Therapeutics (purchased in 2019 by Integra Lifesciences), Rist Neurovascular (purchased in 2020 by Medtronic), Sense Diagnostics, Serenity Medical, Silk Road Medical, Songbird Therapy, Spinnaker Medical, StimMed, Synchron, Three Rivers Medical, Truvic Medical, Tulavi Therapeutics, Vastrax, VICIS, and Viseon AFD: Consulting fees from Cerenovus, Penumbra, Medtronic, Stryker, Oculus, and Koswire. No relevant relationships RD: No relevant relationships PK: No relevant relationships. VK: No relevant relationships. PL: No relevant relationships SB: No relevant relationships CJS: Participation on the data safety monitoring board or advisory board for Zoll Circulation JK: No relevant relationships PJ: No relevant relationships ST: No relevant relationships FC: No relevant relationships NL: Honoraria for lectures from Cerenovus, Stryker, and CrossMed. MAA: Funding to institution from MicroVention for WEBIT trial; proctoring fees from MicroVention. HHC: No relevant relationships CC: Consulting fees from MicroVention, Stryker, Medtronic, MIVI, and Cerenovus. ABP: Grant to institution from Medtronic; consulting fees from MicroVention, Medtronic, and Q’Apel; workstation for research from Siemens AAD: No relevant relationships Publisher Copyright: © Author(s) (or their employer(s)) 2022. No commercial re-use. See rights and permissions. Published by BMJ.

PY - 2022

Y1 - 2022

N2 - Background: The Woven EndoBridge (WEB) device is a novel intrasaccular flow disruptor tailored for bifurcation aneurysms. We aim to describe the degree of aneurysm occlusion at the latest follow-up, and the rate of complications of aneurysms treated with the WEB device stratified according to rupture status. Methods: Our data were taken from the WorldWideWeb Consortium, an international multicenter cohort including patients treated with the WEB device. Aneurysms were classified into two groups: ruptured and unruptured. We compared clinical and radiologic outcomes of both groups. Propensity score matching (PSM) was done to match according to age, gender, bifurcation, location, prior treatment, neck, height, dome width, daughter sac, incorporated branch, pretreatment antiplatelets, and last imaging follow-up. Results: The study included 676 patients with 691 intracranial aneurysms (529 unruptured and 162 ruptured) treated with the WEB device. The PSM analysis had 55 pairs. In both the unmatched (85.8% vs 84.3%, p=0.692) and matched (94.4% vs 83.3%, p=0.066) cohorts there was no significant difference in the adequate occlusion rate at the last follow-up. Likewise, there were no significant differences in both ischemic and hemorrhagic complications between the two groups. There was no documented aneurysm rebleeding after WEB device implantation. Conclusion: There was no significant difference in both the radiologic outcomes and complications between unruptured and ruptured aneurysms. Our findings support the feasibility of treatment of ruptured aneurysms with the WEB device.

AB - Background: The Woven EndoBridge (WEB) device is a novel intrasaccular flow disruptor tailored for bifurcation aneurysms. We aim to describe the degree of aneurysm occlusion at the latest follow-up, and the rate of complications of aneurysms treated with the WEB device stratified according to rupture status. Methods: Our data were taken from the WorldWideWeb Consortium, an international multicenter cohort including patients treated with the WEB device. Aneurysms were classified into two groups: ruptured and unruptured. We compared clinical and radiologic outcomes of both groups. Propensity score matching (PSM) was done to match according to age, gender, bifurcation, location, prior treatment, neck, height, dome width, daughter sac, incorporated branch, pretreatment antiplatelets, and last imaging follow-up. Results: The study included 676 patients with 691 intracranial aneurysms (529 unruptured and 162 ruptured) treated with the WEB device. The PSM analysis had 55 pairs. In both the unmatched (85.8% vs 84.3%, p=0.692) and matched (94.4% vs 83.3%, p=0.066) cohorts there was no significant difference in the adequate occlusion rate at the last follow-up. Likewise, there were no significant differences in both ischemic and hemorrhagic complications between the two groups. There was no documented aneurysm rebleeding after WEB device implantation. Conclusion: There was no significant difference in both the radiologic outcomes and complications between unruptured and ruptured aneurysms. Our findings support the feasibility of treatment of ruptured aneurysms with the WEB device.

KW - Aneurysm

UR - http://www.scopus.com/inward/record.url?scp=85135199475&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85135199475&partnerID=8YFLogxK

U2 - 10.1136/jnis-2022-019153

DO - 10.1136/jnis-2022-019153

M3 - Article

C2 - 35868856

AN - SCOPUS:85135199475

SN - 1759-8478

JO - Journal of neurointerventional surgery

JF - Journal of neurointerventional surgery

M1 - neurintsurg-2022-019153

ER -

Intrasaccular flow disruption for ruptured aneurysms: An international multicenter study

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this